Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Standard BioTools Inc.
Standard BioTools Inc. News
Standard BioTools Inc. Quantitative Score
About Standard BioTools Inc.
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California.
Standard BioTools Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Standard BioTools Inc. Financials
Table Compare
Compare LAB metrics with: | |||
|---|---|---|---|
Earnings & Growth | LAB | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | LAB | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | LAB | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | LAB | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Standard BioTools Inc. Income
Standard BioTools Inc. Balance Sheet
Standard BioTools Inc. Cash Flow
Standard BioTools Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Standard BioTools Inc. Executives
| Name | Role |
|---|---|
| Dr. Michael Egholm Ph.D. | President, Chief Executive Officer & Director |
| Mr. Hanjoon Kim | Chief Financial Officer |
| Mr. Sean Mackay | Chief Business Officer & Senior Vice President |
| Ms. Elizabeth R. Jensen | Chief Human Resources Officer |
| Mr. Jonathan Mickelsen | Vice President & Chief Accounting Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Michael Egholm Ph.D. | President, Chief Executive Officer & Director | 1963 | 1.21M | |
| Mr. Hanjoon Kim | Chief Financial Officer | Male | 1971 | 714.51K |
| Mr. Sean Mackay | Chief Business Officer & Senior Vice President | Male | 1982 | 599.75K |
| Ms. Elizabeth R. Jensen | Chief Human Resources Officer | Female | 1974 | -- |
| Mr. Jonathan Mickelsen | Vice President & Chief Accounting Officer | Male | -- |
Standard BioTools Inc. Insider Trades
| Date | 2 Dec |
| Name | Casdin Partners Master Fund, L.P. |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 125000 |
| Date | 3 Dec |
| Name | Casdin Partners Master Fund, L.P. |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 75000 |
| Date | 4 Dec |
| Name | Casdin Partners Master Fund, L.P. |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 150000 |
| Date | 24 Nov |
| Name | Casdin Partners Master Fund, L.P. |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 150000 |
| Date | 25 Nov |
| Name | Casdin Partners Master Fund, L.P. |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 7550000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 2 Dec | Casdin Partners Master Fund, L.P. | Director, 10 percent owner | Acquired | P-Purchase | 125000 |
| 3 Dec | Casdin Partners Master Fund, L.P. | Director, 10 percent owner | Acquired | P-Purchase | 75000 |
| 4 Dec | Casdin Partners Master Fund, L.P. | Director, 10 percent owner | Acquired | P-Purchase | 150000 |
| 24 Nov | Casdin Partners Master Fund, L.P. | Director, 10 percent owner | Acquired | P-Purchase | 150000 |
| 25 Nov | Casdin Partners Master Fund, L.P. | Director, 10 percent owner | Acquired | P-Purchase | 7550000 |